BRAF — a tumour-agnostic drug target with lineage-specific dependencies
BRAF — a tumour-agnostic drug target with lineage-specific dependencies
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
In June 2022, the FDA granted Accelerated Approval to the BRAF inhibitor dabrafenib in combination with the MEK inhibitor trametinib for the treatment of adult and paediatric patients (≥6 years of age) with unresectable or metastatic
BRAF
V600E
-mutant solid tumours, except for
BRAF
V600E
-mutant colorectal cancers. The histology-...
Alternative Titles
Full title
BRAF — a tumour-agnostic drug target with lineage-specific dependencies
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11857949
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11857949
Other Identifiers
ISSN
1759-4774,1759-4782
E-ISSN
1759-4782
DOI
10.1038/s41571-023-00852-0
